A systems-guided approach to discover the intracellular target of a novel evolution-drug lead

Understanding intracellular antibiotic targeting and the associated mechanisms leading to bacterial growth inhibition has been a difficult problem. Here, we discovered the additional intracellular targets of the novelevolution-drug lead CD15-3 designed to delay the emergence of antibiotic resistance by inhibiting bacterial DHFR and its Trimethoprim resistant variants. Overexpression of DHFR only partially rescued inhibition of E. coli growth by CD15.3 suggesting that CD15.3 also inhibits a non-DHFR target in the cell. We utilized untargeted global metabolomics and the metabolic network analysis along with structural similarity search of the putative targets to identify the additional target of CD15-3. We validated in vivo and in vitro that besides DHFR CD15-3 inhibits HPPK (folK), an essential protein upstream of DHFR in bacterial folate metabolism. This bivalent cellular targeting makes CD15-3 a promising lead to develop a monotherapy analogue of combination drugs.

[1]  Jaie C. Woodard,et al.  Metabolic response to point mutations reveals principles of modulation of in vivo enzyme activity and phenotype , 2019, Molecular systems biology.

[2]  E. Shakhnovich,et al.  Development of antibacterial compounds that block evolutionary pathways to resistance , 2020, 2011.01098.

[3]  Amy K. Cain,et al.  How antibiotics work together: molecular mechanisms behind combination therapy. , 2020, Current opinion in microbiology.

[4]  A. Godzik,et al.  FATCAT 2.0: towards a better understanding of the structural diversity of proteins , 2020, Nucleic Acids Res..

[5]  Anne Richelle,et al.  Creation and analysis of biochemical constraint-based models using the COBRA Toolbox v.3.0 , 2019, Nature Protocols.

[6]  M. Tyers,et al.  Drug combinations: a strategy to extend the life of antibiotics in the 21st century , 2019, Nature Reviews Microbiology.

[7]  S. Halperin.  The structure of (S) , 2019 .

[8]  Adam M. Feist,et al.  iML1515, a knowledgebase that computes Escherichia coli traits , 2017, Nature Biotechnology.

[9]  U. Sauer,et al.  Nontargeted Metabolomics Reveals the Multilevel Response to Antibiotic Perturbations. , 2017, Cell reports.

[10]  Isabel M. Vincent,et al.  Untargeted Metabolomics To Ascertain Antibiotic Modes of Action , 2016, Antimicrobial Agents and Chemotherapy.

[11]  E. Shakhnovich,et al.  Systems-level response to point mutations in a core metabolic enzyme modulates genotype-phenotype relationship. , 2015, Cell Reports.

[12]  N. Shoresh,et al.  Optimization of lag time underlies antibiotic tolerance in evolved bacterial populations , 2014, Nature.

[13]  Yue Li,et al.  Structural enzymology and inhibition of the bi‐functional folate pathway enzyme HPPK–DHPS from the biowarfare agent Francisella tularensis , 2014, The FEBS journal.

[14]  Kazuyuki Shimizu,et al.  Regulation Systems of Bacteria such as Escherichia coli in Response to Nutrient Limitation and Environmental Stresses , 2013, Metabolites.

[15]  M. Cooper,et al.  Antibiotics in the clinical pipeline in 2013 , 2013, The Journal of Antibiotics.

[16]  F. Corona,et al.  The intrinsic resistome of bacterial pathogens , 2013, Front. Microbiol..

[17]  J. Newman,et al.  Exploring the Chemical Space around 8-Mercaptoguanine as a Route to New Inhibitors of the Folate Biosynthesis Enzyme HPPK , 2013, PloS one.

[18]  Rainer Breitling,et al.  IDEOM: an Excel interface for analysis of LC-MS-based metabolomics data , 2012, Bioinform..

[19]  J. Newman,et al.  Structure of S. aureus HPPK and the Discovery of a New Substrate Site Inhibitor , 2012, PloS one.

[20]  E. Shakhnovich,et al.  Soluble oligomerization provides a beneficial fitness effect on destabilizing mutations , 2011, Proceedings of the National Academy of Sciences.

[21]  Arkady B Khodursky,et al.  The association of DNA damage response and nucleotide level modulation with the antibacterial mechanism of the anti-folate drug Trimethoprim , 2011, BMC Genomics.

[22]  R. Breitling,et al.  PeakML/mzMatch: a file format, Java library, R library, and tool-chain for mass spectrometry data analysis. , 2011, Analytical chemistry.

[23]  J. Rabinowitz,et al.  Metabolomics in drug target discovery. , 2011, Cold Spring Harbor symposia on quantitative biology.

[24]  James Inglese,et al.  Comparison of bioluminescent kinase assays using substrate depletion and product formation. , 2009, Assay and drug development technologies.

[25]  Scott J. Hultgren,et al.  Morphological plasticity as a bacterial survival strategy , 2008, Nature Reviews Microbiology.

[26]  L. Silver.  Multi-targeting by monotherapeutic antibacterials , 2007, Nature Reviews Drug Discovery.

[27]  S. Alexeeva,et al.  Use of Thymine Limitation and Thymine Starvation To Study Bacterial Physiology and Cytology , 2006, Journal of bacteriology.

[28]  J. Nielsen,et al.  Uncovering transcriptional regulation of metabolism by using metabolic network topology. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Pecht,et al.  Cold Spring Harbor Symposia on Quantitative Biology , 2005, Protoplasma.

[30]  J. Derrick,et al.  The folic acid biosynthesis pathway in bacteria: evaluation of potential for antibacterial drug discovery. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[31]  A. Eisenstark,et al.  Thymine metabolism and thymineless death in prokaryotes and eukaryotes. , 1998, Annual review of microbiology.

[32]  P. Huovinen,et al.  TRIMETHOPRIM RESISTANCE , 1986, The Lancet.